Saffron (*Crocus sativus*) petal as a new pharmacological target: a review

Azar Hosseini 1, Bibi Marjan Razavi 2,3 Hossein Hosseinzadeh 3,4*

1 Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad Iran
2 Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
4 Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

**ABSTRACT**

Saffron petal is the main by-product of saffron processing which produced at high level but it is not applied and thrown out. Saffron petal is containing of several compounds such as mineral agents, anthocyanins, flavonoids, glycosides, alkaloids and kaempferol. As saffron petal is cheaper and produces in large amounts compared to saffron stigma, so, it can be considered as an appropriate source for different purposes. In this review different pharmacological properties of saffron petal such as antibacterial, antispasmodic, immunomodulatory, antitussive, antidepressant, antinociceptive, hepatoprotective, renoprotective, antihypertensive, antioxidant activity have been introduced. According to these properties, saffron petal can be used as an alternative or supplementary medicine in some diseases.

**Introduction**

*Crocus sativus* (saffron) Linn. is belonging to Iridaceae family. It is used in foods as color and flavor agent and also used in cosmetic preparations (1). In comparison to other parts of plant, the stigma has more applications in food, cosmetic and treatment of diseases. Phytochemical studies have shown saffron stigma is containing crocetin, crocin, picrocrocin and safranal (2). The color of saffron is related to presence of crocin, while pharmacological properties is linked to crocetin (2). Also other components are found in saffron as flavonoids, anthocyanins, vitamins such as riboflavin and thiamine, proteins, starch, amino acids, mineral matter and gums (2). In traditional medicine, it is used as an aphrodisiac, antispasmodic, expectorant, stomachache, relieving tension, depression and insomnia. Also the powdered stigma of saffron was used in treatment of cataract. Other traditional applications are antibacterial, antispasmodic, immunomodulatory, antitussive, antidepressant, antinociceptive, hepatoprotective, renoprotective, antihypertensive, antioxidant activity have been introduced. According to these properties, saffron petal can be used as an alternative or supplementary medicine in some diseases.

Based on evidences, most studies are about stigma of saffron and there is low information about saffron petal. In this review, we collected all studies about saffron petal properties and its pharmacological effects.

**Methods**

This review was written according to finding data from scientific databases such as Scopus, Web of Science, PubMed and local references which investigated different pharmacological properties of saffron petal. These data were collected through electronic databases from their inception to February 2018.

**Chemical compounds**

Saffron petal is containing protein (10.20%), fat (5.3%), ash (7.00%), fiber (5.3%), sodium (25.77 mg/100 g), potassium (542.13 mg/100 g), calcium (486.25 mg/100 g), copper (0.87 mg/100 g), iron (17.99 mg/100 g), magnesium (2.93 mg/100 g), zinc (1.80 mg/100 g) and phosphorus (209.90 mg/100 g) (17). Also it is composed of flavonoles (kaempferol, 12.6%w/w) (18, 19) carotenoids (crocin, 0.6%w/w and crocetin) (19) anthocyanins (20) phenolic compounds (21) terpenoids and alkaloids (22) For first time, the HR-MAS NMR spectroscopy, showed the presence of kinsenoside, goodyeroside A and 3-hydroxy-γ- butyrolactone in intact saffron petal (23). The analysis of ethanolic extract of saffron...
petal by HR-NMR confirmed the presence of these compounds. In addition, the presence of kaempferol 3-O-3-sophoroside has been reported by “NMR-silent” in intact petals (23). The stigma and petal are containing terpenoids such as crocusatins with antityrosinase activity (24). Also, the petal includes anthocyanin which causes the purple color of saffron (24). Depending on pH, anthocyanins may be red, blue, or purple (25). The new monoterpenoids include crocusatin-J, 4-dihydroxybutyric acid were isolated from methanolic extract of saffron petal. Among the different isolated compounds, crocusatin-K, crocusatin-L, and 4-hydroxy-3,5,5-trimethylcyclohex-2-enone show antityrosinase activity while protocatechuic acid, kaempferol, and kaempferol 7-O-β-D-glucopyranoside scavenge R.R-diphenyl-α-picrylhydrazyl (DPPH) radicals more than R-tocopherol (24) (Figure 1).

### Saffron petal properties

Nowadays, saffron petal is used as an organic agent in agriculture industries (26). The phytochemical studies have reported the presence of flavonoids and anthocyanins in saffron petal which showed beneficial effects as supplementary compounds (19). In traditional medicine, saffron petal is consumed as antispasmodic, stomachic, curative of anxiety, antitumor and antidepressant. According to economical properties, phytochemical compounds and traditional usage, it can be used in different medicinal fields (27).

### Pharmacological properties

#### Antibacterial

Food poisoning is caused via eating contaminated foods, toxic plants, fungi or animal materials via entering of bacteria to body. However, using of antimicrobial agents or preservatives can be effective in prevention of bacterial growth (28). The studies have shown some of natural products such as essential oils, herbs and spices have antimicrobial or antifungal properties, therefore can be used as antimicrobial agents (29, 30). The methanolic extract of saffron petal showed antibacterial activity against *Staphylococcus*.

| Compound          | Amount        |
|-------------------|---------------|
| Protein (17)      | 10.20%        |
| Fat (17)          | 5.3%          |
| Ash (17)          | 7%            |
| Fiber (17)        | 8.80%         |
| Sodium (17)       | 25.75 mg/100 g|
| Potassium (17)    | 542.13 mg/100 g|
| Calcium (17)      | 406.25 mg/100 g, 542.13 mg/100 g |
| Copper (17)       | 0.87 mg/100 g |
| Iron (17)         | 17.99 mg/100 g|
| Magnesium (17)    | 2.93 mg/100 g |
| Zinc (17)         | 1.00 mg/100 g |
| Phosphorus zinc (17) | 209.90 mg/100 g |
| Kaempferol (18)   | 12.69μg/w    |
| Crocin (19)       | 0.69μg/w     |
| Anthocyanins (20) | 1712 mg/extract |
| Phenolic compounds (21) | 3.42 mg |
| Terpenoids (21)   | -             |
| Alkaloids (17)    | -             |

**Figure 1.** Chemical structures of some major bioactive constituents of saffron petal. A) kaempferol; B) crocin; C) crocetin; D) kinsenoside; E) goodyeroside A; F) crocusatin-K; G) crocusatin-L.
**Pharmacological effects of saffron petal**

**Hosseini et al.**

*Iran J Basic Med Sci, Vol. 21, No. 11, Nov 2018*

**aureus, Bacillus cereus, Salmonella typhi, Escherichia coli** and *Shigella dysenteriae* at concentration of 1000 mg/ml, with inhibition zone diameters ranging from 13 to 22 mm. The ethyl acetate extract prevented the growth of *B. cereus* with inhibition zone diameter of 15 mm. The water and chloroform extracts had lesser activity against mentioned strains. Based on this study, methanolic, ethyl acetate and aqueous extracts exhibited antimicrobial activity against *S. dysenteriae* (Table 2, Figure 2) (31).

### Antispasmodic effects

The rat isolated vas deferens and guinea pig isolated ileum were used to investigate effect of saffron petal on tonicity of smooth muscle. The petal extracts reduced electrical field stimulation (EFS)-induced contraction in rat isolated vas deferens. In rat isolated vas deferens, petal extracts reduced responses to epinephrine. However, Fatehi *et al.* showed that petal extract antagonized the adrenergic receptors of rat isolated vas deferens. Also, EFS induced contraction in guinea-pig isolated ileum through muscarinic receptors. The petal extract decreased EFS-induced contraction via inhibition of muscarinic receptors (Table 2, Figure 2) (32).

### Immune system

The most of herbal medicines have immunomodulatory effects and alter immune function. The role of herbal medicines in modulation of cytokine secretion, histamine release, immunoglobulin secretion, cellular co-receptor expression, lymphocyte activation and phagocytosis has been reported in different studies (33-35)). In a study conducted on rats received saffron petal extract at doses of 0, 75, 150, 225, and 450 mg/kg for 14 days, no difference between treated groups with control in hematological parameters such as red blood cells, hemoglobin, hematocrit, and platelet has been observed. Saffron petal extract increased IgG at dose of 75 mg/kg in comparison with other groups. No damage was shown in spleen according to the results of pathology. This study showed that saffron petal had immune-stimulatory effect at dose of 75 mg/kg (Table 2, Figure 2) (36).

### Premenstrual syndrome (PMS)

In a double blind clinical study, the women (20-45 years) who experienced PMS symptoms for at least 6 months, received saffron petal twice a day (15 mg/kg at morning and 15 mg/kg at evening). The control group received placebo capsule twice a day. The protocol was done for two menstrual cycles (cycles 3 and 4). The results showed saffron petal improved PMS in comparison with control group (Table 2, Figure 2) (37).

### Antitussive activity

The antitussive activity of *C. sativus* (stigma and petal) and it active ingredients (safranal and crocin) was investigated in guinea pigs using nebulized solution of citric acid 20%. The agents were injected intraperitoneally. The ethanolic extract of *C. sativus* at doses of 100-800 mg/kg and safranal at doses of 0.25-0.75 ml/kg decreased the number of coughs significantly. The ethanolic (200, 400, 800 mg/kg) and aqueous (80, 160, 320 mg/kg) extracts of petal and crocin (50, 200, 600 mg/kg) did not improve cough (Table 2, Figure 2) (7).

### Antidepressant effects

Depression is a psychological disorder which influences thought, behavior and mood. The depressed persons miss their hope and energy for doing of activities. The uncontrolled of depression may lead to suicide. However, the treatment of depression is important. There are different ways for the treatment but using of antidepressant drugs are the most common. These drugs influence the level of neurotransmitters in brain. Whereas, these drugs have positive effects but can cause side effects in long term. Nowadays, the studies have reported that herbal medicine can be effective in mood disorders (38). Different studies have reported saffron plays an important role in modulation of mood (39). A double-blind randomized, placebo-controlled trial showed consumption of saffron stigma (15 mg/Bid for 8 weeks) reduced the symptoms of postpartum depression in breast feeding mothers (40). Also, antidepressant activity of aqueous and ethanolic extracts of saffron...
| Effect                     | Study design | Dose/duration of study                                                                 | Results                                                                 | Ref. |
|----------------------------|--------------|---------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------|
| Antibacterial              | In vitro     | Chloroform, ethyl acetate, methanolic and water extracts were used against different  | Methanol, ethyl acetate and aqueous extracts inhibited the growth of     | (31) |
|                            |              | strains at doses of 31.2, 62.5, 125, 250, 500 and 1000 mg/ml                         | bacteria with different potencies. The effect is related to presence of  |      |
|                            |              |                                                                                        | phenolic compounds and anti-oxidant activity                           |      |
| Muscle relaxant            | In vitro     | EFS-induced contraction in isolated vas deferens and guinea-pig ileum at dose of 560  | Contractility in both of preparations via blocking of postsynaptic       | (32) |
|                            |              | mg/ml                                                                                 | receptors. It can be related to antagonistic effect of the aqueous       |      |
|                            |              |                                                                                        | extract on adrenergic receptors of rat isolated vas deferens            |      |
| Immuno stimulator          | In vivo (rat)| 0, 75, 150, 225, and 450 mg/kg for 14 days.                                           | No change on RBC, Hb, Hct, and platelets; T IgG at dose of 75 mg/kg;    | (36) |
| Premenstrual syndrome (PMS)| Human        | 15 mg/kg at morning and 15 mg/kg at evening                                            | Improvement of PMS, may be due to effect on serotonergic system        | (37) |
| Antihypertensive            | In vivo (rat)| 50mg/100g                                                                             | ↓ MABP                                                                  | (32) |
| Antitussive                | In vivo      | The ethanolic extract of C. sativus (100-800 mg/kg), safranal (0.25-0.75 ml/kg),     | ↓ Number of coughs by ethanolic extract and safranal. The ethanolic and  | (7)  |
|                            |              | ethanolic (200, 400, 800 mg/kg) and aqueous (80, 160, 320 mg/kg) extracts of petal    | aqueous extracts of petal and crocin did not improve cough              |      |
|                            |              | and crocin (50, 200, 600 mg/kg) were injected intraperitoneally with nebulized       |                                                                          |      |
|                            |              | solution of citric acid 20% in guinea pigs                                            |                                                                          |      |
| Antidepressant             | Human        | Saffron stigma (15 mg/Bid for 8 weeks) on postpartum depression in breast feeding      | ↓ symptoms                                                              | (40) |
|                            |              | mothers                                                                               |                                                                          |      |
|                            | In vivo      | Crocin (12.5, 25 and 50 mg/kg) for 21 days in rats.                                    | ↓ immobility time                                                       | (41) |
|                            |              |                                                                                        | ↓ expression of BDNF and CREB and VGF in hippocampus                    |      |
|                            | Human        | at dose of 30 mg/day (b.d.) for 6-weeks                                               | ↓ Signs of depression may be due to increase the level of serotonin     | (43, |
|                            | In vivo (mice |                                                                                        |                                                                          | 44)  |
|                            | and rat)     |                                                                                        |                                                                          |      |
|                            | In vivo (mice)|                                                                                        |                                                                          |      |
|                            |              | Saffron stigma (0.0.8g/kg), safranal (0.15-0.5ml/kg) and crocin (50-600mg/kg)        | ↓ Immobility time in mice and rat                                       | (45) |
|                            |              |                                                                                        | ↓ Immobility time by saffron stigma, safranal and crocin.                |      |
|                            |              |                                                                                        | ↓Swimming time by safranal and extracts of stigma may be due to          |      |
|                            |              |                                                                                        | uptake inhibition of dopamine, oepinephrine and serotonin               |      |
| Antinociceptive and        | In vivo      | Saffron petal                                                                          | ↓ pain induced by chemical compounds and chronic inflammation           | (10) |
| antiinflammatory           |              |                                                                                        |                                                                          |      |
Pharmacological effects of saffron petal

Hosseini et al.

Continued Table 2

| Pharmacological effect | Model | Treatment | Results |
|------------------------|-------|-----------|---------|
| Antidyslipidemia       | In vivo | stigma (40mg/kg), petal (80 mg/kg) and combination (80 mg/kg) for 3 weeks | ↓TG, LDL, leptin, insulin resistant, AST, ALT and ALP, LDL/HDL and TC/HDL (74, 76) |
| Antidiabetic           | In vivo | 100 or 200 mg/kg, orally, in STZ-diabetic rats for 28 days | ↓IFBS and BUN without changing Cr, through reducing extracellular matrix accumulation and its antioxidant properties (76) |
| Carbon tetrachloride   | In vivo | 1 g/kg after 1 and 6h after CCl4 injection | ↓AST and ALT improve anti-oxidant enzymes ↓ liver lesion. may be due to antioxidant activity and radical scavenging, reduction of CCl4 metabolic activation by cytochrome P450 inhibition and fixation of hepatic cell membrane (51) |
| Acetaminophen          | In vivo | 10 and 20 mg/kg for 6 days | ↓AST, ALT, bilirubin and improvement of albumin due to anti-oxidant activity (55) |
| Gentamicin             | In vivo | 40 and 80 mg/kg for 7 days. | could not reduce peliosis hepatic and telangiectasis induced by gentamicin (57) |
| Cisplatin              | In vivo | hydroalcoholic saffron petal (40 and 80 mg/kg) were gavaged for 8 weeks. | Total protein and albumin, ↓AST, ALT, bilirubin and MDA levels related to anti-oxidant properties (60) |

| Renal protective       | In vivo | 10 and 20 mg/kg for 8 days | ↓uric acid, cr and renal injury at high dose (61) |

Red blood cell (RBC), Hemoglobin (Hb), Hematocrit (Hct), Alanine Aminotransferase (ALT), Aspartate transaminase (AST), Alkaline phosphatase (ALP), Fast blood sugar (FBS), Blood urea nitrogen (BUN), Total cholesterol (TC), Triglyceride (TG), Molondialdehyde (MDA), Low density lipoprotein (LDL), High density lipoprotein (HDL) and Mean arterial blood pressure (MABP), brain-derived neurotrophic factor (BDNF), cAMP response element binding protein (CREB) and creatinine (Cr)

Stigma, safranal and crocin were evaluated in mice by force swimming test. The immobility time reduced by saffron stigma (0.0.8 g/kg), safranal (0.15-0.5 ml/kg) and crocin (50-600 mg/kg). Safranal and both extracts of stigma increased swimming time (11). In another study, male Wistar rats received crocin at doses of 12.5, 25 and 50 mg/kg for 21 days. The immobility time in forced swimming test reduced by crocin. Also crocin at doses of 25 and 50 mg/kg, increased the expression of brain-derived neurotrophic factor (BDNF) and cAMP response element binding protein (CREB) in hippocampus. Crocin at all doses increased the level of VGF (41). However, anti-depressant activity of crocin may be related to increase of CREB, VGF and BDNF (41). Also, in other study, rats received aqueous extract of saffron at doses of (40, 80 and 160 mg/kg/day) for 21 days. Results showed, saffron reduced immobility time in forced swimming test. Also, saffron increased BDNF and CREB in hippocampus (42). A double-blind, randomized and placebo-controlled trial showed the efficacy of C. sativus petal in the treatment of mild-to-moderate depression for 6-weeks. In this study, the patients received C. sativus petal as capsule at dose of 30 mg/day (BID) for 6-weeks. While control group received placebo capsule for the mentioned time. After 6 weeks, according to the Hamilton Depression Rating Scale, C. sativus petal showed better antidepressant effect than placebo (43). In another clinical study the antidepressant effect of saffron petal was similar to fluoxetine (44). The adverse effects were not observed in both groups. However, the petal extract plays an effective role in treatment of mild to moderate depression (43). In comparison with saffron stigma, the saffron petal is cheaper, however using of safranal and extracts of stigma may be due to chemical compounds resistant, AST, ALT and ALP. liver lesion. may be due to antioxidant activity and radical scavenging, reduction of CCl4 metabolic activation by cytochrome P450 inhibition and fixation of hepatic cell membrane.

Antinociceptive and anti-inflammatory effects

C. sativus and its constituent safranal have shown preventive effects on serum inflammatory markers in sensitized guinea pigs (46-48). The antinociceptive and anti-inflammatory effects of ethanolic and aqueous...
extracts of saffron petal were investigated in mice. The results showed both of extracts had anti-nociceptive effects against chemical-induced pain. Also, the ethanolic extract reduced chronic inflammation and did not affect on acute inflammation. The observed effects may be related to presence of compounds such as flavonoids, tannins, anthocyanins, alkaloids, and saponins (Table 2, Figure 2) (10).

**Hepatoprotective**

*Carbon tetrachloride (CCL4)*

Carbon tetrachloride is a toxic agent for liver and leads to injuries via fatty degeneration, cellular necrosis, fibrosis and cirrhosis (49). Antioxidants and free radical scavengers can protect liver cells against chemical-induced hepatotoxicity (50). The aqueous extract of petal can protect liver cells against chemical-fibrosis and cirrhosis (49). Antioxidants and free radical leads to injuries via fatty degeneration, cellular necrosis, fibrosis and cirrhosis (49). Antioxidants and free radical scavengers can protect liver cells against chemical-induced hepatotoxicity (50). The aqueous extract of petal reduced chronic inflammation and did not affect on acute inflammation. The observed effects may be related to presence of compounds such as flavonoids, tannins, anthocyanins, alkaloids, and saponins (Table 2, Figure 2) (10).

**Acetaminophen**

Acetaminophen is used commonly as an analgesic and antipyretic drug. Acetaminophen is metabolized and converted to N-acetyl-p-benzoquinone imine (NAPQI) by cytochrome P450 enzymes (52). At therapeutic doses of acetaminophen, the level of produced metabolite is small but at overdose, liver generates high level of NAPQI (53). The high production of NAPQI causes the depletion of glutathione and liver injuries. Oxidative stress happens in hepatic cells following reduction of glutathione (54). The rats were pretreated with *C. sativus* petal at doses of 10 and 20 mg/kg for 6 days, then acetaminophen was administrated orally at dose of 600 mg/kg. Following acetaminophen injection, the amount of AST, ALT and bilirubin increased, while total protein and albumin reduced. *C. sativus* petal at dose of 20 mg/kg restored the acetaminophen toxicity by reduction of AST, ALT and bilirubin levels and improved serum albumin values. The pathological injuries observed in acetaminophen group were cell swelling, severe inflammation and necrosis, while, *C. sativus* petal led to mild injury at high dose (Table 2, Figure 2) (55).

**Gentamicin**

One type of liver injury is identified by blood-filled cavities. Some of diseases including AIDS, tuberculosis, cancer and consumption of drugs such as anabolic steroids and azathioprine cause the above problem (56). A study investigated the protective effect of saffron petal against gentamicin-induced peliosis hepatis in rats. The rats received gentamicin at dose of 80mg/kg for 7 days. Saffron petal was administrated at doses of 40 and 80 mg/kg for 7 days. Neither doses of saffron could reduce peliosis hepatic and telangiectasia induced by gentamicin (Table 2, Figure 2) (57).

**Cisplatin**

Cisplatin as a chemotherapeutic drug induces hepatotoxicity. The side effect of cisplatin is related to oxidative stress and production of ROS, which damages cell membrane. Also, antioxidant enzymes reduced cisplatin injury (58) (59). In a study, the rats were received cisplatin (0.4 mg/kg) for 8 weeks and silymarin as well as hydro-alcoholic saffron petal (40 and 80 mg/kg) were gavaged for 8 weeks. Cisplatin reduced antioxidant enzymes, increased malondialdehyde (MDA) and led to liver injury. The extract and silymarin decreased AST, ALT, MDA and bilirubin levels while increased total protein and albumin levels in serum. Silymarin and hydro-alcoholic saffron petal reduced the toxicity of cisplatin via anti-oxidant properties (Table 2, Figure 2) (60).

**Renoprotective**

*Acetaminophen*

In a study, acetaminophen was injected to rats at dose of 600 mg/kg. Also, saffron petal extract was administered at doses of 10 and 20 mg/kg for 8 days. Acetaminophen increased creatinine and uric acid levels as well as pathological changes in renal. While the extract at high dose reduced renal toxicity via reduction of uric acid and creatinine levels (Table 2, Figure 2) (61).

**Metabolic syndrome**

The metabolic syndrome is complex of problems including diabetes, cardiovascular problems, obesity, nonalcoholic fatty liver disease and kidney dysfunction (62). Different studies have shown herbal medicine play role in reduction of metabolic syndrome symptoms. For example natural products such as *Garcinia mangostana* (63), *Berberis vulgaris* (64), *Camellia sinensis* (green tea) (65), *Persea americana* (Avocado) (66), *Cinnamomum verum* (Cinnamon) (67), *Rosmarinus officinalis* (Rosemary) (68), *Vitis vinifera* (Grape) (69), *Allium sativum* (70) and *Nigella sativa* L (71). Recent studies have shown, saffron and its constituents have protective effects on metabolic syndrome (72). Different studies have reported therapeutic effects of saffron petal on risk factors of metabolic syndrome such as obesity, hypertension and diabetes.

**Antihypertensive activity**

The effect of *C. sativus* petal extract was investigated on blood pressure in anesthetized rats. The aqueous and ethanolic extracts of *C. sativus* petal extract reduced blood pressure at dose of 50 mg/100 g. The reduction of blood pressure could be related to effect of *C. sativus* on heart or peripheral resistance. In this study administration of extract did not change hear rate. However, results showed the effect of extract on peripheral resistance is important factor in decrease of blood pressure (Table 2, Figure 2) (52).

**Antiobesity and Antidyslipidemia**

Obesity is an epidemic disease in worldwide. The chronic obesity is an important factor for metabolic syndrome. The obesity is accompanied with hypertension, insulin resistance, and hyperlipidemia (73). In a study the effect of saffron petal and stigmas were investigated in overweight rats. The rats were received high-fat diet for 10 weeks. Then saffron stigma (40 mg/kg), petal (80 mg/kg) and combination of them (80 mg/
kg) were gavaged to rats for 3 weeks. The results showed the extracts decreased total cholesterol, triglyceride and LDL, while, increased HDL levels. Also the extracts reduced atherosclerosis-index (LDL/HDL), atherogenic index (TC/HDL), and the liver enzymes including ALT, AST and alkaline phosphatase (ALP). The levels of leptin and insulin were reduced by saffron extracts. Results indicated that saffron extracts enhanced antioxidant level, while, reduced lipid peroxidation. However, the extracts ameliorated dyslipidemia in obese rats via reduction of atherosclerosis and insulin resistant (Table 2, Figure 2) (74).

**Antidiabetic**

Streptozotocin (STZ) is a toxic compound for pancreatic β cells. This compound damages pancreatic β cells and leads to lower insulin level and elevates blood glucose (75). In STZ-diabetic rats, saffron petal extract was given orally at doses of 100 or 200 mg/kg for 28 days. STZ increased fasting blood sugar (FBS), urine volume, blood urea nitrogen (BUN), and creatinine (Cr) levels. The extract at dose of 200 mg/kg reduced FBS, while, urine volume and BUN level decreased by both of doses. The level of Cr was not changed by saffron petal. Also the extract improved the histological damages induced by STZ. According to this study, extract protected against STZ-induced nephropathy (Table 2, Figure 2) (76).

**Antioxidant activity**

Reactive oxygen species lead to different diseases via formation of superoxide anion radical, hydroxyl radical, and hydrogen peroxide, which damage cell membrane and attack molecules such as DNA, protein, lipids and small cellular molecules (77). Most of herbal medicines are containing anti-oxidant compounds which scavenge free radicals and reduce cellular damage. A study showed antioxidant activity of saffron petal in lambs using the 2, 2-diphenyl-1-picrylhydrazyl (DPPH) free-radical method. The extracts of saffron petal were gavaged at doses of 500, 1000 and 1500 mg/kg for 15 days. At last day of trial, results showed that saffron petal increased anti-oxidant content at all doses. The extract did not change the levels of glucose, uric acid, creatinine, AST, ALT, ALP, MDA, total thiol, BUN and other indexes (Table 2) (78).

**Antitumor activity**

Anti-tumor activity of saffron stigma and petal was evaluated using brine shrimp and potato disk. Results showed that the IC50 values of saffron extracts were 5.3mg/ml and 10.8 mg/ml for petal and stigma extracts respectively (Table 2, Figure 2) (79).

**Toxicity of saffron petal**

According to toxicological studies, toxicity of stigma is more than petal. Study reported that consumption of 1.2 g saffron led to diarrhea, bleeding, nausea and vomiting (3). For determination of LD50, different doses of saffron stigma and petal were injected to rats intraperitoneally (IP) and the mortality was evaluated after 24 hr. The LD50 values of saffron stigma and petal in mice were 1.6 and 6 g/kg, respectively (80). In a sub-acute toxicity study, saffron stigma was injected IP at doses of 0.16, 0.32 and 0.48 g/kg, while, petal was administrated at doses of 1.2, 2.4 and 3.6 g/kg for two weeks. This study reported that saffron petal and stigma extracts reduced body weight, hematocrit, hemoglobin and erythrocytes. Pathological examination showed stigma did not cause damage in different organs significantly, while, liver and lung injuries were observed in animals received saffron petal (80).

**Conclusion**

This review showed that saffron petal is composed of different active ingredients such as anthocyanins, flavonoles (kaempferol), new monoterpenoids include crocusatin-J and 4-dihydroxybutyric acid. Among the different isolated compounds, crocusatin-K, crocusatin-L, and 4-hydroxy-3,5,5-trimethylcyclohex-2-ene show antityrosinase activity while protocatechuic acid, kaempferol, and kaempferol 7-O-α-D-glucopyranoside scavenge R,R-diphenyl-α-picrylhydrazyl (DPPH) radicals more than R-tocopherol. Saffron petal is cheaper and produces in large amounts compared to saffron stigma, so, it can be considered as an appropriate source for different purposes. It has different pharmacological effects such as antibacterial, hepatoprotective, renoprotective, antidiabetic, antihypertensive, antidysslipidemia, antidepressant, antioxidant and antitumor properties. The most of pharmacological effects is related to the presence of active components in saffron petal which most of them exhibit anti-oxidant activities. According to this review, saffron petal can be used as an alternative or supplementary drug in medicine. Of course, it should be noted that the most of studies which mentioned in this review are animal and clinical studies are low. However, it is necessary to do more human studies.

**Conflicts of Interest**

The authors declare not to have any conflicts of interest.

**References**

1. Fernández JA. Biology, biotechnology and biomedicine of saffron. Recent Res Dev Plant Sci 2004; 2: 127-159.
2. Rios J, Recio M, Giner R, Manez S. An update review of saffron and its active constituents. Phytother Res 1996;10:189-193.
3. Schmidt M, Betti G, Hensel A. Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr 2007;157:315-319.
4. Hosseinzadeh H, Nassiri-Asl M. Aviceenna’s ( Ibn Sina) the canon of medicine and saffron (Crocus sativus) : a review. Phytother Res 2013;27:475-83.
5. Mollazadeh H, Emami SA, Hosseinzadeh H. Razi’s Al-Hawi and saffron (Crocus sativus) : a review. Iran J Basic Med Sci 2015;18:1153-1166.
6. Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, Tsatsakis AM. The effects of Coccus sativus (saffron) and its constituents on nervous system: A review. Avicenna J Phytomed 2015;5:376-391.
7. Hosseinzadeh H, Gheimati J. Evaluation of the antitussive effect of stigma and petals of saffron (Crocus sativus) and its components, safranal and crocin in guinea pigs. Fitoterapia 2006;77:446-448.
8. Asdaq SMB, Inamdar MN. Potential of Crocus sativus (saffron) and its constituent, crocin, as hypolipidemic and antioxidant in rats. Appl Biochem Biotechnol 2010;162:358-372.
9. Hosseinzadeh H, Khosravan V. Anti-convulsant effects of...
aqueous and ethanolic extracts of *Crocus sativus* L stigma in mice. Arch Iran Med 2002; 5:44-47.
10. Hosseinzadeh H, Younesi HM. Antinociceptive and anti-inflammatory effects of *Crocus sativus* L. stigma and petal extracts in mice. BMC Pharmacol 2002; 1: 2-7.
11. Hosseinzadeh H, Karimi G, Niapoor M, editors. Antidepressant effect of *Crocus sativus* L. stigma extracts and its constituents, crocin and safranal, in mice. J Med Plants Res 2004; 3:48-50.
12. Hosseinzadeh H, Noraei NB. Amyloxytic and hypnotic effect of *Crocus sativus* aqueous extract and its constituents, crocin and safranal, in mice. Phythother Res 2009; 23:768-774.
13. Imenshahidi M, Hosseinzadeh H, Javadvour Y. Hypotensive effect of aqueous saffron extract (*Crocus sativus* L.) and its constituents, safranal and crocin, in normotensive and hypertensive rats. Phythoter Res 2010; 2:490-994.
14. Abdullah F, Espinosa-Aguirre J. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. Cancer Detect Prev 2004; 28:426-432.
15. Hosseinzadeh H, Sadeghnia HR, Ziaee T, Daniaee A. Protective effect of aqueous saffron extract (*Crocus sativus* L.) and crocin, its active constituent, on renal ischemia-reperfusion-induced oxidative damage in rats. J Pharm Pharmacol 2005; 58:387-393.
16. Hosseinzadeh H, Shamisaie F, Mehri S. Antioxidant activity of aqueous and ethanolic extracts of *Crocus sativus* L stigma and its bioactive constituents, crocin and safranal. Pharmagoc Mag 2009; 5:419-424.
17. Fahim NK, Janati SF, Feizy J. Chemical composition of agriproduct saffron (*Crocus sativus* L.) petals and its considerations as animal feed. GIAD J Food 2012;3:197-201.
18. Hadizadeh F, Khalihi N, Hosseinzadeh H, Khair-Aldine R. Kämpferol from saffron petals. Iran J Pharm Res 2003; 2: 251-252.
19. Eka K, Ruparelia KC, Continenza MA, Stagos D, Vegliò F, Arroo RR. Petals of *Crocus sativus* and *gossypium hirsutum* and primary growth of cotton (*Crocus sativus* L.) petals and Stamens as Natural Antibacterial Agents Against Food-Borne Bacterial Strains. Iran J Pharm Sci 2013; 9:69-82.
20. Fateh M, Rashidabad T, Fatehi-Hassanabad Z. Effects of *Crocus sativus* petals’ extract on rat blood pressure and on responses induced by electrical field stimulation in the rat isolated vas deferens and guinea-pig ileum. J Ethnopharmacol 2003; 84:199-203.
21. Patwardhan B, Gautam M. Botanical immunodrugs: scope and opportunities. Drug Discov Today 2005; 10:495-502.
22. Plaeger SF. Clinical immunology and traditional herbal medicines. Clin Diagn Lab Immunol 2003; 10:337-338.
23. Zeinali M, Rezaee SA, Hosseinzadeh H. An overview on immunoregulatory and anti-inflammatory properties of chrysirin and flavonoids substances. Biemed Pharmacother 2017; 92:998-1009.
24. Babaei A, Arshami J, Haghparast A, Mesgaran MD. Effects of saffron (*Crocus sativus*) petal ethanolic extract on hematocrit, antibody response, and spleen histology in rats. Avicenna J Phytomed 2014; 4:103-109.
25. Agha-Hosseini M, Kashani L, Aseyase A, Ghoreishi A, Rahmanpour H, Zarrinara A, et al. *Crocus sativus* L(saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG: An Int J Obst Gynaecol 2008;115:515-519.
26. Bikomo E, Ebuehi O, Magbagbeola O. Antidepressant Activity of Ethanol Leaf Extract of *Annona muricata* L., in Sprague-Dawley Rats. Am J Biochem 2017;7:1-5.
27. Karimi GR, Hosseinzadeh H, Khaleghpanah P. Study of antidepressant effect of aqueous and ethanolic extract of *Crocus sativus* in mice. Iran J Basic Med Sci 2001; 4: 11-15.
28. Tabeshpour J, Sobhani F, Sadjadi SA, Hosseinzadeh H, Mohajeri SA, Rajabi O, et al. A double-blind, randomized, placebo-controlled trial of saffron stigma (*Crocus sativus* L) in mothers suffering from mild-to-moderate postpartum depression. Phytomed 2017;36:145-152.
29. Hassan V, Naseri V, Razavi BM, Mehri S, Ahnous K, Hosseinzadeh H. Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus. Daru J Pharm Sci 2014;22:16.
30. Agha-Hosseini M, Kashani L, Aseyase A, Ghoreishi A, Rahmanpour H, Zarrinara A, et al. *Crocus sativus* L(saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG: An Int J Obst Gynaecol 2008;115:515-519.
31. Asgarpanah J, Darahi-Mahboub E, Mahhoubi A, Mehrab R, Hakemivala M. In-Vitro Evaluation of *Crocus Sativus* L. Petals and its constituent (thymoquinone): a review on antimicrobial effects. Iran J Basic Med Sci 2014; 17:929-938.
32. Aghaparanj J, Darahi-Mahboub E, Mahhoubi A, Mehrab R, Hakemivala M. In-Vitro Evaluation of *Crocus Sativus* L. Petals and its constituent (thymoquinone): a review on antimicrobial effects. Iran J Basic Med Sci 2014; 17:929-938.
33. Hosseinízadeh H, Noraei NB. Amyloxytic and hypnotic effect of *Crocus sativus* aqueous extract and its constituents, crocin and safranal, in mice. Phythother Res 2009;23:768-774.
34. Hosseini et al. Pharmacological effects of saffron petal. Iran J Basic Med Sci, Vol. 21, No. 11, Nov 2018.
Pharmacological effects of saffron petal

Hosseini et al.

2007;2:367-370.

46. Gholamnezhad Z, Koushyhar H, Byrami G, Boskabady MH. The extract of *Crocus sativus* and its constituent safranal, affect serum levels of endothelin and total protein in sensitized guinea pigs. Iran J Basic Med Sci 2013;16:1022-1026.

47. Boskabady MH, Fardhondeh T. Antiinflammatory, antioxidant, and immunomodulatory effects of *Crocus sativus*L. and its main constituents. Phytother Res 2016;30:1072-1094.

48. Boskabady MH, Rahbordar MG, Jafari Z. The effect of safaranal on histamine (H1) receptors of guinea pig tracheal chains. Fitoterapia 2011;82:162-167.

49. Maniubian MK, Odin M, Eastmond DA. Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health Part C 2007;25:185-209.

50. Kamalakkanan N, Rukkumani R, Varma PS, Viswanathan P, Rajasekharan KN, Menon VP. Comparative Effects of Curcumin and an Analogue of Curcumin in Carbon Tetrachloride-Induced Hepatotoxicity in Rats. Basic Clin Pharmacol Toxicol 2005;97:15-21.

51. Iranshahi M, Khoshangoht M, Mohammadkhani Z, Karimi G. Protective effects of aqueous and ethanolic extracts of *Crocus* stigma and petal on liver toxicity induced by carbon tetrachloride in mice. Pharmacologynline 2011;1:203-212.

52. Bunchorntavakul C, Reddy KR. Acetaminophen-related tetrachloride in mice. Pharmacologyonline 2011;1:203-212.

53. Tan SC, New LS, Chan EC. Prevention of acetaminophen hepatotoxicity. Clin Liver Dis 2013;17:587-607.

54. Hinson JA, Roberts DW, James LP. Mechanisms of *N*-acetyl-p-benzoquinone imine. Toxicol Let 2008;180:174-181.

55. San JW, Chen YS, Chang MH, Lin MY. Protective effects of *Crocus sativus* against acetaminophen toxicity in male Wistar rats. Handb Exp Pharmacol 2010;196:369-405.

56. Omidi A, Riahinia N, Torbati MBM, Behdani M-A. Hepatoprotective effect of *Crocus sativus* (saffron) petals against acetaminophen toxicity in male Wistar rats. Avicenna J Phytomed 2014;4:330-336.

57. Nakamura Y. Non-neoplastic nodular lesions in the liver. Pathol Int 1995;45:703-714.

58. Omidi A, Torabi Z, Hassanpoorfard M, Zardast M. Evaluation of protective effect of hydroalcoholic extract of *Crocus sativus* petals on preventing of gentamicin induced peliosis hepatis and hepatic telangiectasis in rats. J Birjand Univ Med Sci 2013;19:445-462.

59. Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 1999;33:438-434.

60. Robbins ME, Zhao W, Davis CS, Toyokuni S, Bonsib SM. Radiation-induced kidney injury: a role for chronic oxidative stress? Micron 2002;33:133-141.

61. Dariush DY. Protective effects of *Crocus sativus* and its main constituents. Phytother Res 2016;30:1072-1094.

62. Kassi E, Pervanidou P, Kaltasag S, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48-60.

63. Tousian HS, Razavi BM, Hosseinzadeh H. Review of *Garcinia mangostana* and its xanthones in metabolic syndrome and related complications. Phytother Res 2017;31:1173-1182.

64. Tabeshpour J, Imenshahidi M, Hosseinzadeh H. A review of the effects of *Berberis vulgaris* and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci 2017;20:557-568.

65. Razavi BM, Loomian F, Hosseinzadeh H. Protective effects of green tea on olanzapine-induced metabolic syndrome in rats. Biomed Pharmacother 2017;92:726-731.

66. Tabeshpour J, Razavi BM, Hosseinzadeh H. Effects of *Avocado (Persea americana)* on metabolic syndrome: a comprehensive systematic review. Phytother Res 2017;31:819-837.

67. Mollazadeh H, Hosseinzadeh H. Cinnamon effects on metabolic syndrome: a review based on its mechanisms. Iran J Basic Med Sci 2016;19:1258-1270.

68. Hassani FV, Shirani K, Hosseinzadeh H. *Nigella sativa* L. and its constituent, thymoquinone, in metabolic syndrome. J Endocrinol Invest 2014;37:1031-1040.

69. Razavi BM, Hosseinzadeh H. *Nigella sativa* L. as a promising natural medicine in the treatment of metabolic syndrome. J Sci Food Agric 2017;97:1679-1685.

70. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2019;94:2595-2600.

71. Razavi BM, Hosseinzadeh H. *Avocado (Persea americana)* as a potential therapeutic plant in metabolic syndrome: a review. Naunyn-Schmiedeberg's Arch Pharmacol 2016;389:93-1-49.

72. Akaberi M, Hosseinzadeh H. *Grapes (Vitis vinifera)* as a potential candidate for the therapy of the metabolic syndrome. Phytother Res 2016;30:540-556.

73. Hosseini A, Hosseinzadeh H. A review of the effects of *Garlic* (*Allium sativum*) on metabolic syndrome. J Clin Endocrinol Metab 2015;38:1147-1157.

74. Hoshyar R, Hosseinian M, Naghandar MR, Hemmati M, Zarban A, Amini Z, et al. Anti-dyslipidemic properties of *Saffron* (*Crocus sativus*): A review of the effects of *Berberis vulgaris* and its major component, *Berberine*, in metabolic syndrome: a review based on its mechanisms. Phytother Res 2016;30:540-556.

75. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2019;94:2595-2600.

76. Hosseinian M, Naghandar MR, Hemmati M, Zarban A, et al. Anti-dyslipidemic properties of *Saffron* (*Crocus sativus*): A review of the effects of *Berberis vulgaris* and its major component, *Berberine*, in metabolic syndrome: a review based on its mechanisms. Phytother Res 2016;30:540-556.

77. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2019;94:2595-2600.